StockData
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. (LRMR) stock

LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$2.99−0.01 (-0.33%)

Close on Nov 17, 2026Market cap $310.61MP/E –Yield –

Larimar Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Larimar Therapeutics's revenue for the twelve months ending Mar 31, 2020 was $0. For fiscal 2019 it was $0. The highest annual figure on record is $0 in fiscal 2012.

Annual revenue

PeriodPeriod endValueChange
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–
FY2015Dec 31, 2015$0–
FY2014Dec 31, 2014$0–
FY2013Dec 31, 2013$0–
FY2012Dec 31, 2012$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2020Mar 31, 2020$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$0–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$0–

More Larimar Therapeutics figures

See a number that looks wrong?